Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
Formiga et al., J. Control Release, doi:10.1016/j.jconrel.2020.10.009 (Review)
Formiga et al., Ivermectin: an award-winning drug with expected antiviral activity against COVID-19, J. Control Release, doi:10.1016/j.jconrel.2020.10.009 (Review)
Jan 2021   Source   PDF  
  All Studies   Meta
Review hypothesizing that micro- and nanotechnology-based formulations of ivermectin for the pulmonary delivery of ivermectin may be beneficial for use with COVID-19.
Formiga et al., 10 Jan 2021, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Journal of Controlled Release 329 (2021) 758–761 Contents lists available at ScienceDirect Journal of Controlled Release journal homepage: Ivermectin: an award-winning drug with expected antiviral activity against COVID-19 Fabio Rocha Formiga a, b, *, Roger Leblanc c, Juliana de Souza Rebouças d, Leonardo Paiva Farias e, Ronaldo Nascimento de Oliveira f, Lindomar Pena g a Department of Immunology, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ), 50670-420 Recife, PE, Brazil Graduate Program in Applied Cellular and Molecular Biology, University of Pernambuco (UPE), 50100-130 Recife, PE, Brazil Department of Chemistry, University of Miami, 1301 Memorial Drive, Coral Gables, FL 33146, USA d Institute of Biological Sciences, University of Pernambuco (UPE), 50100-130 Recife, PE, Brazil e Laboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), 40296-710 Salvador, BA, Brazil f Bioactive Compounds Synthesis Laboratory, Department of Chemistry, Federal Rural University of Pernambuco (UFRPE), 52171-900 Recife, PE, Brazil g Department of Virology, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ), 50670-420 Recife, PE, Brazil b c A B S T R A C T Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin’s activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns. 1. Commentary The 2015 Nobel Prize in Physiology and Medicine was awarded to William C. Campbell and Satoshi Ömura for their discoveries leading to ivermectin [1]. In addition to its extraordinary efficacy against parasitic diseases, ivermectin continues to offer new clinical applications due to its ability to be repurposed to treat new classes of diseases. Beyond its invaluable therapeutic role in onchocerciasis and strongyloidiasis, an increasing body of evidence points to the potential of ivermectin as an antiviral agent. Ivermectin treatment was shown to increase survival in mice infected with the pseudorabies virus (PRV) [2] and reduced titers of porcine circovirus 2 (PCV2) in the tissues and sera of infected piglets [3]. In addition, Xu et al...
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop